|
Jean,
I think part of the problem has been that medicine lacked the tools to examine the effect of tx on molecular subtypes, and that subset analysis in clinical trials for these molecular profiles has not been the norm. As more information is gathered, and trials are designed around molecular phenotype, the tide will change.
Hopeful
|